Zacks Research Has Negative Forecast for Novavax Q4 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Stock analysts at Zacks Research reduced their Q4 2026 earnings estimates for Novavax in a research note issued on Wednesday, February 26th. Zacks Research analyst S. Ganoria now forecasts that the biopharmaceutical company will earn $0.40 per share for the quarter, down from their previous estimate of $0.45. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share.

Other analysts also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $19.00 target price on shares of Novavax in a research report on Tuesday, December 10th. BTIG Research began coverage on shares of Novavax in a research report on Friday. They set a “buy” rating and a $19.00 price objective for the company. Finally, TD Cowen upgraded shares of Novavax to a “hold” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Novavax presently has an average rating of “Hold” and an average price target of $18.00.

Novavax Price Performance

Shares of NASDAQ:NVAX opened at $8.33 on Friday. The business’s 50 day simple moving average is $8.51 and its 200 day simple moving average is $9.98. Novavax has a 1 year low of $3.81 and a 1 year high of $23.86. The company has a market capitalization of $1.33 billion, a P/E ratio of -3.69, a P/E/G ratio of 2.85 and a beta of 2.14.

Novavax (NASDAQ:NVAX) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.24. The business had revenue of $88.31 million for the quarter, compared to analyst estimates of $85.48 million. During the same quarter in the previous year, the company earned ($1.44) EPS.

Insider Buying and Selling at Novavax

In other news, Director Rachel K. King sold 4,150 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the sale, the director now directly owns 14,770 shares in the company, valued at approximately $133,225.40. This trade represents a 21.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director James F. Young sold 5,400 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the transaction, the director now owns 51,760 shares of the company’s stock, valued at approximately $414,080. This represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock worth $119,641 over the last 90 days. Insiders own 1.00% of the company’s stock.

Institutional Trading of Novavax

Hedge funds have recently made changes to their positions in the company. Sanofi bought a new position in Novavax in the 4th quarter valued at approximately $55,319,000. Deep Track Capital LP bought a new position in shares of Novavax during the fourth quarter valued at $16,080,000. State Street Corp raised its stake in shares of Novavax by 26.7% during the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock valued at $97,099,000 after acquiring an additional 1,621,772 shares during the last quarter. Shah Capital Management lifted its holdings in shares of Novavax by 13.6% during the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock worth $89,637,000 after purchasing an additional 1,333,305 shares during the period. Finally, Two Sigma Advisers LP grew its stake in shares of Novavax by 48.9% in the third quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company’s stock worth $25,252,000 after purchasing an additional 656,900 shares during the last quarter. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.